Colleen Olive

Summary

Affiliation: Queensland Institute of Medical Research
Country: Australia

Publications

  1. ncbi request reprint Lipoamino acid-based adjuvant carrier system: enhanced immunogenicity of group a streptococcal peptide epitopes
    Aniko Horvath
    School of Pharmacy, The University of Queensland, Brisbane QLD 4072, Australia
    J Med Chem 45:1387-90. 2002
  2. ncbi request reprint Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia
    J Infect Dis 194:316-24. 2006
  3. ncbi request reprint Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Division of Infectious Diseases and Immunology, Herston, Brisbane, QLD 4029, Australia
    Vaccine 23:2298-303. 2005
  4. ncbi request reprint Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research PO Royal Brisbane Hospital, University of Queensland, Brisbane Queensland, Australia
    Indian J Med Res 119:88-94. 2004
  5. ncbi request reprint Lipid core peptide technology and group A streptococcal vaccine delivery
    Colleen Olive
    Co operative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia
    Expert Rev Vaccines 3:43-58. 2004
  6. ncbi request reprint Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, Queensland Institute of Medical Research, Brisbane, Australia
    J Infect Dis 193:1666-76. 2006
  7. pmc Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, Division of Infectious Diseases and Immunology, The Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia
    Infect Immun 71:2373-83. 2003
  8. ncbi request reprint Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, QLD 4029, Australia
    Vaccine 20:2816-25. 2002
  9. pmc A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies
    Colleen Olive
    Division of Infectious Diseases and Immunology, Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia
    Infect Immun 70:2734-8. 2002
  10. ncbi request reprint Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice
    Linda A Dunn
    Division of Infectious Diseases and Immunology, Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, P O Royal Brisbane Hospital, QLD 4029, Brisbane, Australia
    Vaccine 20:2635-40. 2002

Collaborators

Detail Information

Publications28

  1. ncbi request reprint Lipoamino acid-based adjuvant carrier system: enhanced immunogenicity of group a streptococcal peptide epitopes
    Aniko Horvath
    School of Pharmacy, The University of Queensland, Brisbane QLD 4072, Australia
    J Med Chem 45:1387-90. 2002
    ..Furthermore, the peptides incorporated into the LCP system generated epitope-specific antibodies without the use of any conventional adjuvant...
  2. ncbi request reprint Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia
    J Infect Dis 194:316-24. 2006
    ..We investigated the lipid core peptide (LCP) system for mucosal vaccine delivery against infection with group A streptococcus (GAS)--the causative pathogen of rheumatic fever and rheumatic heart disease...
  3. ncbi request reprint Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Division of Infectious Diseases and Immunology, Herston, Brisbane, QLD 4029, Australia
    Vaccine 23:2298-303. 2005
    ..These data indicate that protective immunity to GAS infection can be evoked using the self-adjuvanting LCP system, and point to the potential application of this system in human mucosal GAS vaccine development...
  4. ncbi request reprint Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research PO Royal Brisbane Hospital, University of Queensland, Brisbane Queensland, Australia
    Indian J Med Res 119:88-94. 2004
    ..In this study, we investigated the lipid polylysine core peptide (LCP) system as a self-adjuvanting GAS vaccine delivery approach...
  5. ncbi request reprint Lipid core peptide technology and group A streptococcal vaccine delivery
    Colleen Olive
    Co operative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia
    Expert Rev Vaccines 3:43-58. 2004
    ..This review aims to cover the various strategies and technologies that have been investigated with regard to group A streptococcus vaccine design and development...
  6. ncbi request reprint Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, Queensland Institute of Medical Research, Brisbane, Australia
    J Infect Dis 193:1666-76. 2006
    ....
  7. pmc Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, Division of Infectious Diseases and Immunology, The Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia
    Infect Immun 71:2373-83. 2003
    ....
  8. ncbi request reprint Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope
    Colleen Olive
    Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, QLD 4029, Australia
    Vaccine 20:2816-25. 2002
    ..These data indicate that immunity to GAS infection can be evoked by intranasal immunisation with a GAS M protein C-region peptide vaccine that contains a protective B cell epitope and lacks a T cell autoepitope...
  9. pmc A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies
    Colleen Olive
    Division of Infectious Diseases and Immunology, Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia
    Infect Immun 70:2734-8. 2002
    ..These data indicate the potential of an LCP-based M protein conserved region GAS vaccine in the induction of broadly protective immune responses in the absence of a conventional adjuvant...
  10. ncbi request reprint Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice
    Linda A Dunn
    Division of Infectious Diseases and Immunology, Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, P O Royal Brisbane Hospital, QLD 4029, Brisbane, Australia
    Vaccine 20:2635-40. 2002
    ..n. but not oral delivery. These data support the potential of the i.n. route in the mucosal delivery of a GAS vaccine...
  11. ncbi request reprint Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation
    Peter M Moyle
    School of Pharmacy and School of Molecular and Microbial Sciences SMMS, University of Queensland, St Lucia, QLD, Australia
    J Org Chem 71:6846-50. 2006
    ..Intranasal immunization of the described tri-epitopic GAS lipopeptide with the mucosal adjuvant cholera toxin B subunit induced high serum IgG antibody titers specific for each of the incorporated peptide epitopes...
  12. ncbi request reprint Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease
    Michael R Batzloff
    The Cooperative Research Centre for Vaccine Technology and the Australian Centre for International Tropical Health and Nutrition, The Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Brisbane 4029, Australia
    Immunol Res 35:233-48. 2006
    ..This review focuses on different M-protein-based-subunit vaccine approaches and the different delivery technologies used to administer these vaccine candidates in preclinical studies...
  13. ncbi request reprint Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines
    Daniel Mitchell
    The Queensland Institute of Medical Research, Brisbane, Australia
    Hum Vaccin 7:85-93. 2011
    ....
  14. doi request reprint Dual stimulation of MyD88-dependent Toll-like receptors induces synergistically enhanced production of inflammatory cytokines in murine bone marrow-derived dendritic cells
    Daniel Mitchell
    Queensland Institute of Medical Research, Herston, Brisbane, Queensland, Australia
    J Infect Dis 202:318-29. 2010
    ..The present study investigated whether simultaneous stimulation of two TLRs that signal through the same or different pathway(s) enhances cytokine production in DCs...
  15. ncbi request reprint Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease
    Colleen Olive
    The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia
    Curr Opin Mol Ther 9:25-34. 2007
    ..The development of subunit vaccine approaches targeting the M protein using various vaccine delivery technologies is the focus of this review...
  16. doi request reprint Regulation of Toll-like receptor-induced chemokine production in murine dendritic cells by mitogen-activated protein kinases
    Daniel Mitchell
    The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia
    Mol Immunol 47:2065-73. 2010
    ..The chemokine response of DCs induced by TLR agonists appears complex and could have important implications for vaccine design...
  17. ncbi request reprint Lipid and carbohydrate based adjuvant/carriers in immunology
    Ross P McGeary
    School of Molecular and Microbial Sciences, The University of Queensland, Brisbane, Queensland, Australia
    J Pept Sci 9:405-18. 2003
    ..There has been a recent increase of interest in the use of lipids and carbohydrates as adjuvants, and so a particular emphasis is placed on adjuvants derived from lipids or carbohydrates, or from both...
  18. doi request reprint Expression of maturation markers on murine dendritic cells in response to group A streptococcal lipopeptide vaccines
    Michelle Yong
    The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia
    Vaccine 27:3313-8. 2009
    ..Our results indicate that an LCP-GAS vaccine induced phenotypic maturation of BM-Flt3-DC but not BM-GMCSF-DC...
  19. doi request reprint Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants
    Colleen Olive
    The Queensland Institute of Medical Research, Locked Bag 2000, Royal Brisbane Hospital, Herston, Brisbane, Queensland 4006, Australia
    Expert Rev Vaccines 11:237-56. 2012
    ..The role of PRR cooperation in generating optimal immune responses required for protective immunity and the potential of targeting PRRs in the development of a new generation of vaccine adjuvants is also discussed...
  20. doi request reprint Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines
    Pavla Simerska
    School of Molecular and Microbial Sciences, The University of Queensland, St Lucia 4072, Queensland, Australia
    J Med Chem 51:1447-52. 2008
    ..High serum IgG antibody titers against each of the incorporated peptide epitopes were detected following subcutaneous immunization of B10.BR (H-2 (k)) mice with the liposaccharide vaccine candidates...
  21. ncbi request reprint Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines
    Peter M Moyle
    School of Pharmacy, The University of Queensland, St Lucia 4072, Queensland, Australia
    J Med Chem 50:4721-7. 2007
    ....
  22. ncbi request reprint Method for the synthesis of highly pure vaccines using the lipid core peptide system
    Peter M Moyle
    School of Molecular and Microbial Biosciences, The University of Queensland, St Lucia, Queensland, Australia
    J Pept Sci 12:800-7. 2006
    ..Subcutaneous immunization of B10.BR (H-2(k)) mice with one of these vaccines, without the addition of any adjuvant, elicited high levels of systemic IgG antibodies against each of the incorporated peptides...
  23. ncbi request reprint Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation
    Peter M Moyle
    School of Pharmacy, The University of Queensland, St Lucia 4072, Queensland, Australia
    J Med Chem 49:6364-70. 2006
    ..Subcutaneous immunization of B10.BR (H-2(k)) mice with the synthesized vaccine, with or without the addition of complete Freund's adjuvant, elicited high serum IgG antibody titers against each of the incorporated peptide epitopes...
  24. pmc Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population
    Nonglak Yoonim
    Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
    BMC Microbiol 6:71. 2006
    ..Then, we examined the bactericidal activity of J14, J14.1, J14-R1 and J14-R2 antisera against multiple Thai GAS strains...
  25. ncbi request reprint Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes
    Kai Schulze
    Department of Vaccinology, GBF German Research Centre for Biotechnology, Mascheroder Weg 1, D 38124 Braunschweig, Germany
    Vaccine 24:6088-95. 2006
    ..The obtained results indicate that in our experimental animal model peptide-based conjugate vaccines represent a valid alternative to protect against streptococcal infection...
  26. pmc M protein typing of Thai group A streptococcal isolates by PCR-Restriction fragment length polymorphism analysis
    Nonglak Yoonim
    Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
    BMC Microbiol 5:63. 2005
    ..To overcome this problem, we have developed a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)-based assay for molecular typing the M protein gene (emm) of GAS...
  27. ncbi request reprint Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage
    Aniko Horvath
    School of Pharmacy and School of Molecular and Microbial Sciences, The University of Queensland, Brisbane 4072, Australia
    J Med Chem 47:4100-4. 2004
    ..The LCP construct, however, elicited excellent antibody responses to all three epitopes without the need for any additional adjuvant or carrier. We have synthesized the LCP synthetic vaccine system with good reproducibility...
  28. ncbi request reprint Induction of autoimmune valvulitis in Lewis rats following immunization with peptides from the conserved region of group A streptococcal M protein
    Robyn S Lymbury
    Microbiology and Immunology, School of Biomedical Sciences, James Cook University, Townsville, Australia
    J Autoimmun 20:211-7. 2003
    ..This study may support the use of the rat model of autoimmune valvulitis to investigate the immunopathogenesis of RHD and possible preventive strategies...